# Biopharma Regulatory Reference: Batch Records, Stability Testing & Adverse Event Monitoring

**Last Updated:** 2026-02-11
**Compiled from:** FDA/eCFR (.gov), ICH (.org), MedDRA (.org) primary sources

---

## Table of Contents

1. [Batch Record Review](#1-batch-record-review)
2. [Stability Testing & Tracking](#2-stability-testing--tracking)
3. [Adverse Event Monitoring & Safety Reporting](#3-adverse-event-monitoring--safety-reporting)

---

## 1. BATCH RECORD REVIEW

### 1.1 Governing CFR Sections

#### 21 CFR 211.188 -- Batch Production and Control Records

**Citation:** [21 CFR 211.188](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.188)

**Plain English:** Every batch of drug product must have a complete written record of everything that happened during its manufacture.

**Required Contents (subsections a-b):**

- **(a)** An accurate reproduction of the appropriate master production or control record, checked for accuracy, dated, and signed.
- **(b)** Documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished, including:
  - Dates and times of each step
  - Identity of individual major equipment and lines used
  - Specific identification of each batch of component or in-process material used
  - Weights and measures of components used in the course of processing
  - In-process and laboratory control results
  - Inspection of the packaging and labeling area before and after use
  - A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing
  - Complete labeling control records, including specimens or copies of all labeling used
  - Description of drug product containers and closures
  - Any sampling performed
  - Identification of the persons performing and directly supervising or checking each significant step in the operation (or if automated equipment under 211.68, the person checking)
  - Any investigation made according to 211.192
  - Results of examinations made in accordance with 211.134

**Record Retention:** At least 1 year after the expiration date of the batch, or 3 years after distribution for OTC products exempt from expiration dating under 211.137.

#### 21 CFR 211.186 -- Master Production and Control Records

**Citation:** [21 CFR 211.186](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.186)

**Plain English:** The "template" or master document from which batch records are derived. Must include the complete manufacturing and control instructions, sampling/testing procedures, and specifications.

**Required Contents:**
- Name and strength of the drug product
- Name and weight/measure of each active ingredient per dosage unit or per unit weight/measure
- Complete list of components designated by names or codes
- Accurate statement of weight/measure of each component
- Statement concerning any calculated excess of component
- Statement of theoretical weight/measure at appropriate phases
- Description of drug product containers, closures, and packaging materials
- Complete manufacturing and control instructions, sampling and testing procedures, specifications, special notations, and precautions

#### 21 CFR 211.192 -- Production Record Review

**Citation:** [21 CFR 211.192](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.192)

**Plain English:** Quality control must review and approve every batch record before the batch can be released for distribution. Any discrepancy must be thoroughly investigated.

**Key Requirements:**
- All drug product production and control records, including packaging and labeling, shall be reviewed and approved by the quality control unit
- Review must determine compliance with all established, approved written procedures before batch release or distribution
- Any unexplained discrepancy (including yield percentages exceeding max/min established in master records) or failure to meet specifications shall be **thoroughly investigated**, whether or not the batch has already been distributed
- Investigation shall extend to other batches of the same product and other products that may be associated with the failure or discrepancy
- Written record of investigation shall include conclusions and followup

### 1.2 21 CFR Part 211 Subpart J -- Records and Reports (Complete)

**Citation:** [21 CFR Part 211 Subpart J](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J)

| Section | Title | Key Requirement |
|---------|-------|-----------------|
| 211.180 | General requirements | Records retained >= 1 year after batch expiration; readily available for inspection; annual product quality review required |
| 211.182 | Equipment cleaning and use log | Written record of major equipment cleaning, maintenance, and use showing date, time, product, lot number |
| 211.184 | Component, drug product container, closure, and labeling records | Receipt, identity testing, disposition records for all incoming materials |
| 211.186 | Master production and control records | Template with complete instructions for each drug product |
| 211.188 | Batch production and control records | Executed record for each batch (see detailed breakdown above) |
| 211.192 | Production record review | QC unit review/approval before release; discrepancy investigation |
| 211.194 | Laboratory records | Complete data from all tests; equipment suitability records; reference standards documentation |
| 211.196 | Distribution records | Earliest and latest dates of distribution; name/address of consignee; lot number; quantity shipped |
| 211.198 | Complaint files | Written records of all complaints; formal investigation if complaint involves possible product failure; complaint and investigation records maintained at the establishment where the drug product is manufactured |

### 1.3 ICH Q7 -- Good Manufacturing Practice for Active Pharmaceutical Ingredients

**Citation:** [ICH Q7 Guideline](https://database.ich.org/sites/default/files/Q7%20Guideline.pdf) | [FDA Adoption](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-questions-and-answers)

**Plain English:** The international GMP standard for APIs (active pharmaceutical ingredients). Section 6 covers Documentation and Records.

**Key Requirements (Section 6 -- Documentation and Records):**

- **Section 6.5 -- Batch Production Records:** Shall be prepared for each intermediate and API and include complete information relating to production and control of each batch
  - Batch production record checked before issuance to ensure correct version and legible accurate reproduction of master production instruction
  - Numbered with a unique batch or identification number, dated and signed when issued
  - In continuous production, the product code + date/time can serve as unique identifier until final number is allocated
  - Documentation of completion of each significant step
  - Date and, when appropriate, time
  - Identity of major equipment used
  - Identification of each batch of raw materials, intermediates, or any reprocessed materials
  - Actual results recorded for critical process parameters
  - Any sampling performed
  - Signatures of persons performing and directly supervising/checking each critical step
  - Results of in-process and laboratory testing
  - Actual yield at appropriate phases or times
  - Description of packaging and label of intermediate or API
  - A representative label of API or intermediate if made commercially available
  - Any deviation noted, its evaluation, and investigation conducted (or reference to that investigation)
  - Results of release testing

- **Section 6.6 -- Laboratory Control Records:** Complete data derived from all tests conducted to ensure compliance with established specifications and standards

- **Record Retention:** At least 1 year after the expiry date of the batch. For APIs with retest dates, records retained at least 3 years after batch is completely distributed.

- **Quality Unit Review:** All production batch records reviewed and signed before release. All deviations reported, evaluated; critical deviations investigated with conclusions recorded.

### 1.4 FDA Guidance Documents on Batch Records & Data Integrity

#### Data Integrity and Compliance With Drug CGMP (2018)

**Citation:** [FDA Data Integrity Guidance Q&A](https://www.fda.gov/media/119570/download)

**Key Points:**
- Defines data integrity in the context of CGMP records
- Addresses ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, Available)
- Applies to all CGMP records, whether paper or electronic
- Original data should be maintained; true copies acceptable only when verified as exact copies
- Audit trails should be maintained for electronic records
- Metadata is an integral part of the data and must be retained

#### Data Integrity and Compliance With CGMP -- Draft Guidance (2016)

**Citation:** [FDA Data Integrity Draft Guidance](https://www.fda.gov/media/97005/download)

**Key Points:**
- Clarifies FDA expectations for data integrity across all CGMP areas
- Emphasizes that "data" includes raw data, metadata, and all records
- Staff should not be able to alter, delete, or overwrite data without proper controls
- Backup/archive procedures must protect data throughout its retention period

#### CPG Sec. 425.500 -- Computerized Drug Processing (Batch Records)

**Citation:** [FDA CPG 425.500](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-425500-computerized-drug-processing-identification-persons-batch-production-and-control)

**Key Points:**
- Addresses identification of "persons" on batch production and control records when using computerized systems
- Unique identification codes or passwords acceptable as "identification" under 211.188

#### 21 CFR Part 11 -- Electronic Records; Electronic Signatures

**Citation:** [FDA Part 11 Guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application)

**Key Points:**
- Electronic records are equivalent to paper records if Part 11 compliant
- Electronic signatures are equivalent to handwritten signatures
- Requires audit trails, access controls, and system validation

### 1.5 Specific Data Points in Biologics Batch Records

Per 21 CFR 211.188, ICH Q7, ICH Q6B, and FDA biologics guidance, the following data points must typically be documented in a biologics batch record:

**Process Parameters:**
- Cell culture conditions (temperature, pH, dissolved oxygen, agitation rate)
- Fermentation/bioreactor run time and volume
- Chromatography column performance (pressure, flow rate, eluate volumes)
- Filtration parameters (filter integrity testing pre/post-use)
- Fill volume and fill weight

**In-Process Controls (IPC):**
- Cell viability and cell count
- pH at defined stages
- Osmolality
- Bioburden at intermediate steps
- Protein concentration (A280, BCA, or equivalent)

**Release Testing (per ICH Q6B & 21 CFR 610):**

| Parameter | Regulatory Basis | Notes |
|-----------|-----------------|-------|
| **Identity** | ICH Q6B, 21 CFR 610.14 | Peptide map, Western blot, or equivalent |
| **Purity** | ICH Q6B, 21 CFR 610.13 | SEC-HPLC (aggregation), CE-SDS, HCP, residual DNA |
| **Potency** | ICH Q6B, 21 CFR 610.10 | Bioassay or validated cell-based assay; expressed in units calibrated against reference standard |
| **Strength/Quantity** | ICH Q6B | Protein concentration (UV, ELISA) |
| **Sterility** | 21 CFR 610.12 | USP <71> sterility test (14-day incubation) |
| **Endotoxin** | 21 CFR 610.13(b) | LAL test per USP <85>; limits typically <=5 EU/kg/hr for parenteral biologics |
| **General Safety** | 21 CFR 610.11 | (Being phased out for some products) |
| **Particulate Matter** | USP <787>, <788> | Sub-visible and visible particulates |
| **pH** | USP <791> | Measured on final formulated product |
| **Osmolality** | USP <785> | For injectable products |
| **Appearance** | ICH Q6B | Color, clarity, visible particulates |
| **Container Closure Integrity** | USP <1207> | Dye ingress, vacuum decay, or HVLD |

**Yield Calculations:**
- Theoretical yield vs. actual yield at each critical step
- Percentage of theoretical yield (deviation outside established limits triggers 211.192 investigation)
- Product-related impurities and process-related impurities quantified

### 1.6 Recent Updates (2024-2026)

- **ICH Q7 Q&As** were published providing additional clarification on documentation and record-keeping requirements. No substantive changes to Section 6 requirements.
- **FDA Draft Guidance: "Considerations for Complying with 21 CFR 211.110"** issued January 2025 -- applicable to CDER, CBER, and CVM; addresses in-process controls which are documented in batch records.
- **CBER Guidance Agenda 2026:** CBER is planning guidance documents for Calendar Year 2026 that may include updates relevant to biologics manufacturing records. Specific topics under consideration at [FDA CBER 2026 Guidance Agenda](https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/guidance-agenda-guidance-documents-cber-planning-publish-during-calendar-year-2026).
- **AI in Manufacturing:** FDA issued guidance in January 2025 on "Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products," which has implications for automated batch record systems.
- **No changes to 21 CFR 211.188 text** since the January 2017 eCFR update. The regulatory requirements remain stable.

---

## 2. STABILITY TESTING & TRACKING

### 2.1 ICH Q1A(R2) -- Stability Testing of New Drug Substances and Products

**Citation:** [ICH Q1A(R2) Guideline](https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf) | [FDA Adoption](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products)

**Plain English:** The foundational international guideline for how to design and conduct stability studies for new drugs. Defines storage conditions, testing intervals, and study designs.

**Standard Stability Conditions (Climatic Zones I & II):**

| Study Type | Storage Condition | Minimum Duration |
|-----------|------------------|-----------------|
| **Long-term** | 25 +/- 2 C / 60% +/- 5% RH | 12 months at time of submission; 6 months accelerated |
| **Intermediate** | 30 +/- 2 C / 65% +/- 5% RH | 6 months (triggered if significant change at accelerated) |
| **Accelerated** | 40 +/- 2 C / 75% +/- 5% RH | 6 months |

**Note:** The intermediate condition was harmonized in Q1A(R2) from 30 C/60% RH to **30 C/65% RH** to align with the long-term condition for Climatic Zones III/IV.

**Testing Frequency:**
- **Long-term:** Every 3 months over the first year, every 6 months over the second year, and annually thereafter through the proposed shelf life
- **Accelerated:** Minimum of 3 time points including initial and final (e.g., 0, 3, 6 months)

**Key Principles:**
- Stress testing (forced degradation) is part of development strategy, not formal stability
- Stability studies must use the same container-closure system as the marketed product
- Data from accelerated studies can support tentative expiration dates, but must be verified by long-term data
- Significant change criteria: 5% potency loss, exceeding degradation product limit, failure of appearance/physical properties, failure of pH, or failure of 12 dosage units in dissolution

### 2.2 ICH Q1B -- Photostability Testing

**Citation:** [ICH Q1B Guideline](https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf)

**Plain English:** Defines how to test whether light exposure degrades a drug. Must demonstrate that normal or expected light exposure does not cause unacceptable change.

**Key Requirements:**
- Two-part testing: (1) forced degradation to assess overall photosensitivity, (2) confirmatory testing to establish that the commercial packaging provides adequate protection
- Light exposure: combined NUV (near-UV) and VIS (visible) light meeting defined thresholds
  - Overall illumination >= 1.2 million lux hours
  - Integrated near-UV energy >= 200 watt hours/square meter
- Sequential or simultaneous exposure of drug substance and drug product
- Must include dark controls to distinguish photolytic from thermal degradation

### 2.3 ICH Q1C -- New Dosage Forms

**Citation:** [ICH Q1C Guideline](https://www.fda.gov/media/71715/download)

**Plain English:** Reduced stability data requirements for new dosage forms of already-approved drug substances. Allows leveraging existing stability data.

**Key Requirements:**
- Applies to new dosage forms of an already-approved drug substance
- Abbreviated stability data may suffice if the manufacturer has existing stability data on the drug substance and formulation experience
- Must still conduct accelerated and long-term studies on the new dosage form
- The extent of data needed depends on how different the new dosage form is

### 2.4 ICH Q1D -- Bracketing and Matrixing Designs

**Citation:** [ICH Q1D Guideline](https://database.ich.org/sites/default/files/Q1D%20Guideline.pdf) | [FDA Adoption](https://www.fda.gov/media/71720/download)

**Plain English:** Allows testing a subset of samples rather than every combination of factor levels (strengths, container sizes, etc.), using statistically valid reduced designs.

**Key Principles:**
- **Bracketing:** Testing only the extremes of design factors (e.g., smallest and largest container sizes). Assumes intermediates are represented by extremes.
- **Matrixing:** A reduced testing design where only a fraction of the total number of samples is tested at each time point. All factor combinations are tested, but at different time points.
- Must be scientifically justified based on prior knowledge of formulation and container-closure system behavior
- Not appropriate if significant differences are expected among factor levels

### 2.5 ICH Q1E -- Evaluation of Stability Data

**Citation:** [ICH Q1E Guideline](https://database.ich.org/sites/default/files/Q1E_Guideline.pdf) | [FDA Adoption](https://www.fda.gov/media/71722/download)

**Plain English:** Statistical methods for determining shelf life from stability data, including how to extrapolate beyond the observed data.

**Key Principles:**
- Shelf life (retest period) established from long-term data using statistical methods
- Extrapolation beyond observed data generally limited to no more than twice the period covered by long-term data (but not more than 12 months beyond)
- Regression analysis used to determine the time at which the 95% one-sided confidence limit intersects the acceptance criterion
- Pooling of data across batches permitted if justified statistically (p > 0.25)

### 2.6 21 CFR 211.166 -- Stability Testing

**Citation:** [21 CFR 211.166](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-I/section-211.166)

**Plain English:** The US federal regulation requiring a written stability testing program for all finished pharmaceutical products, with results used to determine storage conditions and expiration dates.

**Complete Requirements:**

**(a)** There shall be a written testing program designed to assess the stability characteristics of drug products. The results of such stability testing shall be used in determining appropriate storage conditions and expiration dates. The written program shall include:
1. Sample size and test intervals based on statistical criteria for each attribute examined to assure valid estimates of stability
2. Storage conditions for samples retained for testing
3. Reliable, meaningful, and specific test methods
4. Testing of the drug product in the same container-closure system as that in which the drug product is marketed
5. Testing of drug products for reconstitution at the time of dispensing (as directed in the labeling) as well as after they are reconstituted

**(b)** An adequate number of batches of each drug product shall be tested to determine an appropriate expiration date and a record of such data shall be maintained. Accelerated studies, combined with basic stability information on the components, drug products, and container-closure system, may be used to support tentative expiration dates provided full shelf life studies are not available and are being conducted. Where data from accelerated studies are used to project a tentative expiration date beyond what is supported by actual shelf life studies, there must be stability studies conducted, including drug product testing at appropriate intervals, until the tentative expiration date is verified or the appropriate expiration date determined.

**(c)** Homeopathic drug products: written assessment of stability based at least on testing for compatibility of ingredients and marketing experience.

**(d)** Allergenic extracts labeled "No U.S. Standard of Potency" are exempt.

**Companion Regulation -- 21 CFR 211.137 (Expiration Dating):** Drug products must bear an expiration date determined by appropriate stability testing per 211.166.

**Companion Regulation -- 21 CFR 211.170 (Reserve Samples):** Reserve samples must be stored under conditions consistent with product labeling.

### 2.7 ICH Q5C -- Stability Testing of Biotechnological/Biological Products

**Citation:** [ICH Q5C Guideline](https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf) | [FDA Adoption](https://www.fda.gov/media/71441/download)

**Plain English:** The specific stability guideline for biologics. Recognizes that biological products are more complex than small molecules and require a broader panel of stability-indicating methods.

**Key Requirements:**

**Testing Frequency for Real-Time Studies:**
- Shelf life <= 1 year: test monthly for first 3 months, then every 3 months thereafter
- Shelf life > 1 year: test every 3 months during first year, every 6 months during second year, annually thereafter

**Storage Conditions:**
- Real-time/real-condition studies at the recommended storage condition (often 2-8 C for biologics)
- Accelerated and stress studies at elevated temperatures to provide understanding of degradation pathways
- For frozen products: studies at the intended storage temperature

**Stability-Indicating Profile (no single assay sufficient):**

| Parameter Category | Examples |
|-------------------|----------|
| **Potency (Biological Activity)** | Cell-based bioassay, binding assay, enzyme activity |
| **Purity & Molecular Integrity** | SEC-HPLC (aggregation/fragmentation), CE-SDS, IEF |
| **Degradation Products** | Oxidation variants, deamidation, clipping |
| **Identity** | Peptide mapping, mass spectrometry |
| **Physicochemical Properties** | pH, color, clarity, appearance, osmolality |
| **Particulate Matter** | Sub-visible particles (USP <787>/<788>), visible particles |
| **Sterility/Container Closure** | Sterility testing, container closure integrity |
| **Quantity** | Protein concentration (A280, UV) |

**Key Principle:** There is no single stability-indicating assay or parameter that profiles the stability characteristics of a biotechnological/biological product. Manufacturers must propose a stability-indicating profile that provides assurance that changes in identity and purity of the product are detected.

### 2.8 Stability Parameters Typically Monitored for Biologics

| Parameter | Method | Acceptance Criteria (typical) |
|-----------|--------|------------------------------|
| Potency | Cell-based bioassay | 80-125% of reference (varies by product) |
| Purity (monomer %) | SEC-HPLC | NLT 95% (mAbs typically) |
| Aggregates (HMW %) | SEC-HPLC | NMT 2-5% |
| Fragments (LMW %) | CE-SDS (reducing/non-reducing) | Product-specific |
| Charge variants | cIEF or IEX-HPLC | Product-specific |
| Oxidation | Peptide mapping + MS | Product-specific |
| Subvisible particulates | Light obscuration (USP <787>) | <=6000 particles >=10um, <=600 particles >=25um per container |
| Visible particulates | Visual inspection | Essentially free from visible particulates |
| pH | USP <791> | +/- 0.3 of target |
| Protein concentration | A280 or ELISA | +/- 10% of label claim |
| Color & appearance | Visual/instrumental | Clear, colorless to pale yellow (mAbs) |
| Sterility | USP <71> | No growth (14-day incubation) |
| Container closure integrity | USP <1207> methods | Pass |
| Endotoxin | LAL per USP <85> | Product-specific limits |

### 2.9 Recent Updates (2024-2026)

#### ICH Q1 Consolidated Revision (Step 2 Draft -- April 2025)

**Citation:** [ICH Q1 Draft Guideline (Step 2)](https://database.ich.org/sites/default/files/ICH_Q1EWG_Step2_Draft_Guideline_2025_0411.pdf) | [ICH Announcement](https://www.ich.org/news/ich-q1-draft-guideline-step-2-presentation-now-available-ich-website)

**THIS IS THE MOST SIGNIFICANT STABILITY UPDATE IN DECADES.**

**What it does:**
- Consolidates ICH Q1A-F and Q5C into a **single unified guideline** (new "ICH Q1")
- Issued as Step 2 draft for public consultation on April 11, 2025
- Based on Concept Paper and Business Plan from November 2022
- Modernizes stability testing approaches for all product types including biologics, biosimilars, and advanced therapies

**Current Status (as of Feb 2026):** Step 2 draft -- under public consultation. NOT yet finalized. The existing Q1A(R2) through Q1F and Q5C remain the current enforceable guidelines until the new Q1 reaches Step 4.

**Key Changes in Draft:**
- Knowledge- and risk-based approaches to stability study design
- Expanded coverage for product types not comprehensively addressed in current guidelines
- Consolidation of bracketing/matrixing (currently Q1D) into the main guideline
- Updated guidance on photostability testing
- Harmonized approach for chemical and biological products

#### Other Recent Developments:
- **FDA CBER 2025 Guidance Agenda** included stability-related topics under consideration for biologics-specific guidance.
- **FDA ANDAs Stability Q&A Guidance** continues to be updated with questions addressing ICH Q1A(R2) implementation.
- **No changes to 21 CFR 211.166** regulatory text. The regulation remains stable.

---

## 3. ADVERSE EVENT MONITORING & SAFETY REPORTING

### 3.1 21 CFR 312.32 -- IND Safety Reporting

**Citation:** [21 CFR 312.32](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.32) | [FDA Guidance for Sponsors](https://www.fda.gov/media/79394/download)

**Plain English:** The core US regulation governing how sponsors of investigational drugs must report safety information to FDA during clinical trials.

#### Definitions (21 CFR 312.32(a)):

| Term | Definition |
|------|-----------|
| **Adverse event (AE)** | Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related |
| **Serious adverse event (SAE)** | Results in: death, life-threatening AE, inpatient hospitalization (or prolongation), persistent/significant incapacity, congenital anomaly/birth defect, or important medical events requiring intervention |
| **Suspected adverse reaction** | An AE for which there is a reasonable possibility that the drug caused the event ("reasonable possibility" = evidence to suggest causal relationship) |
| **Unexpected** | Not listed in the investigator brochure, or not at the specificity or severity observed |
| **Life-threatening** | Places the patient at immediate risk of death (NOT an event that hypothetically might have caused death if more severe) |

#### Reporting Timelines (21 CFR 312.32(c)):

| Report Type | Timeline | Trigger | Citation |
|------------|----------|---------|----------|
| **IND Safety Report (15-day)** | As soon as possible, no later than **15 calendar days** after sponsor determines info qualifies | Any finding from clinical trials or any other source that suggests a significant risk to trial subjects, including: (i) suspected adverse reaction that is both **serious and unexpected**; (ii) findings from other studies (animal/in vitro) suggesting significant human risk; (iii) increased rate of expected serious suspected adverse reactions; (iv) findings that increase risk of AE | 21 CFR 312.32(c)(1) |
| **7-Day Telephone/Fax Report** | As soon as possible, no later than **7 calendar days** after initial receipt of information | Any **unexpected fatal or life-threatening** suspected adverse reaction | 21 CFR 312.32(c)(2) |
| **15-Day Follow-up to 7-Day Report** | No later than **15 calendar days** after initial 7-day report | Follow-up to the 7-day report with additional relevant information | 21 CFR 312.32(c)(2) |
| **Follow-up Reports** | As soon as the information is available | New information on any previously reported IND safety report | 21 CFR 312.32(d) |

**Electronic Submission:** IND safety reports for serious and unexpected suspected adverse reactions must be submitted electronically per [FDA ESG guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-ind-safety-reports-guidance-industry), using the ICH E2B(R3) ICSR format.

#### What is a SUSAR?

**SUSAR = Suspected Unexpected Serious Adverse Reaction**

A SUSAR is an adverse event that meets ALL three criteria:
1. **Suspected** -- there is a reasonable possibility the drug caused it
2. **Unexpected** -- not listed in the investigator's brochure (or not at the observed specificity/severity)
3. **Serious** -- results in death, life-threatening event, hospitalization, disability, congenital anomaly, or requires medical intervention to prevent such outcomes

SUSARs are the primary trigger for **15-day expedited IND safety reports** under 21 CFR 312.32(c)(1)(i). If the SUSAR is also **fatal or life-threatening**, a **7-day telephone/fax report** is required under 312.32(c)(2).

### 3.2 21 CFR 600.80 -- Postmarketing Reporting for Biologics (BLAs)

**Citation:** [21 CFR 600.80](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600/subpart-D/section-600.80)

**Plain English:** Once a biologic is approved and marketed, the BLA holder must report adverse experiences to FDA. This is the biologics-specific version of postmarketing safety reporting.

**Key Requirements:**

| Report Type | Timeline | Trigger |
|------------|----------|---------|
| **15-Day Alert Report** | As soon as possible, no later than **15 calendar days** from initial receipt | Adverse experience that is **both serious and unexpected** (foreign or domestic) |
| **Follow-up to 15-Day Alert** | Within **15 calendar days** of receipt of new information | New data on any 15-day Alert report |
| **Periodic Safety Reports** | Quarterly for first 3 years after approval, then annually | All adverse experiences not qualifying for 15-day reports |

**Obligations:**
- Must promptly review ALL adverse experience information from ANY source (clinical, epidemiological, literature, spontaneous reports)
- Must develop written procedures for surveillance, receipt, evaluation, and reporting
- Must submit reports electronically to FAERS (FDA Adverse Event Reporting System)
- Must promptly investigate all 15-day Alert report events

### 3.3 ICH E2A -- Clinical Safety Data Management: Definitions and Standards for Expedited Reporting

**Citation:** [ICH E2A Guideline](https://database.ich.org/sites/default/files/E2A_Guideline.pdf) | [FDA Adoption](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2a-clinical-safety-data-management-definitions-and-standards-expedited-reporting)

**Date:** Step 4, October 1994

**Plain English:** The international standard that defines terms (serious, unexpected, etc.) and establishes principles for expedited reporting of adverse drug reactions during clinical development.

**Key Definitions (harmonized internationally):**

- **Adverse Event (AE):** Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product; does not necessarily have a causal relationship
- **Adverse Drug Reaction (ADR):** In the pre-approval context, all noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions
- **Serious:** Death, life-threatening, hospitalization, prolongation of hospitalization, persistent/significant disability, congenital anomaly, or other medically important event
- **Unexpected:** Not consistent with applicable product information (investigator's brochure for unapproved products)

**Expedited Reporting Standard:**
- All cases judged as having a reasonable suspected causal relationship that are both **serious and unexpected** are subject to expedited reporting
- Fatal or life-threatening unexpected ADRs qualify for most rapid reporting (7 days in some regions)
- Sponsors should also report findings from non-clinical studies suggesting significant risk

### 3.4 ICH E2B(R3) -- Electronic Transmission of Individual Case Safety Reports (ICSRs)

**Citation:** [ICH E2B(R3) Specification](https://ich.org/page/e2br3-individual-case-safety-report-icsr-specification-and-related-files) | [FDA Regional Implementation Guide](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-regional-implementation-guide-e2br3-electronic-transmission-individual-case-safety-reports-drug)

**Plain English:** The technical standard for how to format and transmit adverse event reports electronically between companies and regulators worldwide.

**Key Requirements:**
- Based on ISO/HL7 27953-2 standard
- All ICSRs submitted to FDA must use E2B(R3) format via the **FDA Electronic Submissions Gateway (ESG)**
- Replaces earlier E2B(R2) format
- XML-based message structure containing:
  - Patient demographics
  - Drug information (suspect, concomitant, interacting)
  - Reaction/event information (MedDRA coded)
  - Case narrative
  - Reporter information
  - Administrative information

**FDA FAERS II:** The modernized FDA Adverse Event Reporting System accepts E2B(R3) format for pre-market and post-market safety reports.

**2025 Update:** [ICH ICSR Implementation Guide](https://database.ich.org/sites/default/files/ICH_E2B%28R3%29_EWG_IWG_ICSR_Implementation_Guide_%28QA%20integration%29_Step3_2025_0718_Assembly_Approved_0.pdf) reached Step 3 in July 2025, integrating Q&A clarifications into the main implementation guide.

### 3.5 ICH E2F -- Development Safety Update Report (DSUR)

**Citation:** [ICH E2F Guideline](https://database.ich.org/sites/default/files/E2F_Guideline.pdf) | [FDA Adoption](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2f-development-safety-update-report)

**Plain English:** A standardized annual safety report that sponsors must submit for drugs under development. Replaces the FDA IND Annual Report safety section and provides a comprehensive safety analysis.

**Key Requirements:**

- **Frequency:** Annual -- submitted within 60 days of the **Data Lock Point (DLP)**
- **Data Lock Point:** Last day of the one-year reporting period. For convenience, can be designated as last day of the month prior to the Development International Birth Date (DIBD)
- **DIBD:** The date of the first approval (or first clinical trial authorization) to investigate the drug

**Required Content (Sections):**
1. Executive summary
2. Introduction
3. Worldwide marketing approval status
4. Update to actions taken for safety reasons
5. Reference safety information (changes to IB)
6. Findings from clinical trials (interval and cumulative)
7. Findings from non-interventional studies
8. Other clinical trial/study information
9. Non-clinical findings
10. Literature findings
11. Other information
12. Lack of efficacy as a safety concern
13. Late-breaking information
14. Overall safety assessment and conclusions
15. Summary of important risks
16. Appendices (line listings, summary tabulations)

**Synchronization:** When a drug continues development post-marketing approval, the DSUR data lock point should be synchronized with the PSUR/PBRER International Birth Date so that the DSUR and PSUR cover contiguous periods.

### 3.6 ICH E2D(R1) -- Post-Approval Safety Data Management (2025 Finalized)

**Citation:** [ICH E2D(R1) Final Guideline (Step 4, August 2025)](https://database.ich.org/sites/default/files/ICH_E2D%28R1%29_Step4_FinalGuideline_2025_0819.pdf) | [FDA Adoption Page](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e2d-postapproval-safety-data-management-definitions-and-standards-expedited-reporting)

**THIS IS A MAJOR 2025 UPDATE.**

**Plain English:** Revised guideline for managing post-approval safety data. Updates the original 2003 E2D to account for new data sources that have emerged since then.

**Key Updates in R1 (Finalized August 19, 2025; endorsed September 15, 2025):**
- Addresses new sources of post-market safety information including:
  - Patient support programs
  - Social media
  - Digital health technologies
  - Real-world data/evidence
- Updated definitions and standards for expedited reporting in the post-approval setting
- Clarifies expectations for literature screening and signal detection
- Harmonized approach for solicited vs. unsolicited reports

**Status:** Step 4 finalized. Implementation timelines vary by region; check regional regulatory authority for local adoption dates.

### 3.7 MedDRA Coding

**Citation:** [MedDRA Official Site](https://www.meddra.org/) | [ICH MedDRA Page](https://ich.org/page/meddra)

**Current Version (as of Feb 2026):** **MedDRA Version 28.1** (released September 1, 2025)

| Version | Release Date | Notes |
|---------|-------------|-------|
| 28.0 | March 2025 | Major release with changes at all hierarchy levels |
| 28.1 | September 2025 | Simple release -- changes at PT and LLT levels only |
| 29.0 | Expected March 2026 | Next major release |

**MedDRA Hierarchy (5 levels):**

| Level | Abbreviation | Description | Approximate Count |
|-------|-------------|-------------|------------------|
| System Organ Class | SOC | Highest level; body system or etiology | ~27 |
| High-Level Group Term | HLGT | Groups of HLTs within an SOC | ~340 |
| High-Level Term | HLT | Groups of related PTs | ~1,750 |
| Preferred Term | PT | Distinct medical concept for symptoms, diagnoses, indications | ~25,000+ |
| Lowest Level Term | LLT | Synonyms, lexical variants, sub-concepts | ~85,000+ |

**Standardised MedDRA Queries (SMQs):** Pre-defined, validated groupings of MedDRA terms for identifying specific medical conditions (e.g., "Drug-related hepatic disorders -- comprehensive"). Over 110 SMQs available.

**Release Schedule:** Biannual -- March (x.0) and September (x.1).

**Regulatory Requirement:** MedDRA coding is **mandatory** for:
- IND safety reports (21 CFR 312.32)
- Postmarketing AE reports (21 CFR 600.80 / 314.80)
- E2B(R3) ICSR submissions
- DSUR and PSUR/PBRER submissions

### 3.8 CIOMS Forms

**Citation:** [CIOMS I Form](https://cioms.ch/cioms-i-form/) | [CIOMS Form PDF](https://cioms.ch/wp-content/uploads/2017/05/cioms-form1.pdf)

**What:** The Council for International Organizations of Medical Sciences (CIOMS) Form I is a standardized one-page paper form for reporting individual adverse drug reactions internationally.

**When Required:**
- Foreign adverse experiences can be submitted to FDA on either FDA Form 3500A **or** a CIOMS I form
- Used primarily for **international reporting** of suspected adverse drug reactions
- Standard format for case narratives transmitted between regulatory authorities and MAHs internationally
- Largely superseded by electronic E2B(R3) transmission but still accepted as paper format

**CIOMS Form I Data Elements:**
1. Patient initials, age, sex, weight, height
2. Reaction onset date, description, outcome
3. Suspect drug(s): name, daily dose, route, indication, dates of administration
4. Concomitant drugs
5. Reporter information and date
6. Manufacturer/sponsor information
7. Narrative (brief description of the event)

**CIOMS Working Groups -- Historical Significance:**
- CIOMS I (1990): Established the CIOMS form and defined the minimum standard for AE reporting
- CIOMS II (1992): Led to periodic safety update reports (now PSUR/PBRER per ICH E2C(R2))
- CIOMS III/V: Core clinical safety information for drug products
- CIOMS VI (2005): Management of safety information from clinical trials
- These CIOMS Working Group outputs directly influenced ICH guidelines E2A, E2C, E2D, and E2F

### 3.9 FDA Guidance on Safety Reporting for IND Sponsors

**Primary Guidance:** [Safety Reporting Requirements for INDs and BA/BE Studies](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-reporting-requirements-inds-investigational-new-drug-applications-and-babe) (Final, March 2012; current)

**Key Points:**
- Defines when a sponsor should and should not file an IND safety report
- Clarifies that **not every SAE requires an IND safety report** -- only those meeting 312.32(c)(1) criteria
- Emphasizes that aggregate analyses are important for identifying increased rates of expected SAEs
- Provides detailed examples of reportable vs. non-reportable scenarios
- Addresses reporting requirements for combination products and products studied under BA/BE protocols

**Companion Guidance:** [Investigator Responsibilities -- Safety Reporting](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigator-responsibilities-safety-reporting-investigational-drugs-and-devices)

- **Investigators** must report AEs to sponsors per the protocol and 21 CFR 312.64
- **Sponsors** aggregate, evaluate, and submit IND safety reports to FDA
- Investigators do NOT submit IND safety reports directly to FDA (sponsors do)

**Electronic Format Guidance:** [IND Safety Reports Electronic Format](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-ind-safety-reports-guidance-industry)

- IND safety reports for SUSARs per 312.32(c)(1)(i) must be submitted electronically
- Uses ICH E2B(R3) format
- Submitted through FDA Electronic Submissions Gateway (ESG)

### 3.10 ICH E19 -- Selective Approach to Safety Data Collection (2022)

**Citation:** [ICH E19 Guideline](https://database.ich.org/sites/default/files/ICH_E19_Guideline_Step4_2022_0826_0.pdf)

**Plain English:** A newer ICH guideline (Step 4, August 2022) that allows a more targeted approach to safety data collection in specific late-stage or post-approval clinical trials, rather than collecting every AE.

**Relevance:** Reduces reporting burden for well-characterized safety profiles in late-phase trials while maintaining patient safety.

### 3.11 Recent Updates (2024-2026)

| Update | Date | Description |
|--------|------|-------------|
| **ICH E2D(R1) Finalized** | Aug 2025 (Step 4) | Major revision of post-approval safety data management. Addresses social media, patient support programs, digital health as safety data sources. See Section 3.6. |
| **ICH E2B(R3) Implementation Guide (Step 3)** | Jul 2025 | Updated ICSR implementation guide integrating Q&A clarifications. |
| **MedDRA 28.1** | Sep 2025 | Current version. 1,032 change requests approved. |
| **FDA CDER Drug Safety Priorities FY2024** | 2024 | Expanded use of Sentinel tree-based scan statistics for signal detection; AI/ML pharmacovigilance tools under development. |
| **FDA AI Guidance** | Jan 2025 | "Considerations for the Use of AI To Support Regulatory Decision-Making for Drug and Biological Products" -- implications for automated pharmacovigilance. |
| **FDA FAERS II** | Ongoing | Modernized adverse event reporting system using E2B(R3); unified analytics platform. |
| **ICH E2D(R1) Step 2 Draft** | Feb 2024 | Public consultation period for E2D revision (now finalized). |
| **CBER 2026 Guidance Agenda** | Published | CBER planning additional guidance for biologics safety surveillance. See [CBER 2026 Agenda](https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/guidance-agenda-guidance-documents-cber-planning-publish-during-calendar-year-2026). |

---

## Quick Reference: Key Citations Summary

### Batch Records
| Citation | What It Covers |
|----------|---------------|
| 21 CFR 211.186 | Master production and control records |
| 21 CFR 211.188 | Batch production and control records |
| 21 CFR 211.192 | Production record review by QC unit |
| 21 CFR Part 211 Subpart J | All records and reports requirements |
| ICH Q7 Section 6 | API documentation and batch records |
| ICH Q6B | Specifications for biologics (identity, purity, potency) |
| 21 CFR Part 11 | Electronic records and signatures |

### Stability Testing
| Citation | What It Covers |
|----------|---------------|
| 21 CFR 211.166 | Stability testing program requirements |
| 21 CFR 211.137 | Expiration dating |
| ICH Q1A(R2) | Stability testing conditions and design |
| ICH Q1B | Photostability testing |
| ICH Q1C | New dosage forms |
| ICH Q1D | Bracketing and matrixing |
| ICH Q1E | Statistical evaluation of stability data |
| ICH Q5C | Stability testing for biologics |
| ICH Q1 (Draft, 2025) | Consolidated revision of Q1A-F + Q5C |

### Adverse Events & Safety
| Citation | What It Covers |
|----------|---------------|
| 21 CFR 312.32 | IND safety reporting (7-day and 15-day) |
| 21 CFR 600.80 | Postmarketing AE reporting for biologics |
| ICH E2A | Clinical safety definitions and expedited reporting |
| ICH E2B(R3) | Electronic ICSR format and transmission |
| ICH E2D(R1) | Post-approval safety data management (2025 revision) |
| ICH E2F | DSUR (annual development safety reports) |
| ICH E19 | Selective safety data collection |
| MedDRA 28.1 | Current AE coding dictionary (Sep 2025) |
| CIOMS Form I | International AE reporting form |

---

## Sources

### Government Sources (ecfr.gov, fda.gov, govinfo.gov)
- [eCFR 21 CFR 211.188](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.188)
- [eCFR 21 CFR Part 211 Subpart J](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J)
- [eCFR 21 CFR 211.166](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-I/section-211.166)
- [eCFR 21 CFR 312.32](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.32)
- [eCFR 21 CFR 600.80](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600/subpart-D/section-600.80)
- [FDA Data Integrity Q&A Guidance](https://www.fda.gov/media/119570/download)
- [FDA Safety Reporting Requirements for INDs](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-reporting-requirements-inds-investigational-new-drug-applications-and-babe)
- [FDA CBER 2025 Guidance Agenda](https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/guidance-agenda-guidance-documents-cber-planning-publish-during-calendar-year-2025)
- [FDA CBER 2026 Guidance Agenda](https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/guidance-agenda-guidance-documents-cber-planning-publish-during-calendar-year-2026)
- [FDA IND Safety Reports Electronic Format](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-ind-safety-reports-guidance-industry)
- [FDA E2B(R3) Regional Implementation Guide](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-regional-implementation-guide-e2br3-electronic-transmission-individual-case-safety-reports-drug)
- [FDA Q6B Specifications for Biotechnological Products](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6b-specifications-test-procedures-and-acceptance-criteria-biotechnologicalbiological-products)
- [FDA Q5C Stability Testing of Biotechnological Products](https://www.fda.gov/media/71441/download)
- [FDA Q1A(R2) Stability Testing](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products)
- [GovInfo 21 CFR 312.32 (2023)](https://www.govinfo.gov/app/details/CFR-2023-title21-vol5/CFR-2023-title21-vol5-sec312-32)

### ICH Sources (ich.org)
- [ICH Q7 Guideline (GMP for APIs)](https://database.ich.org/sites/default/files/Q7%20Guideline.pdf)
- [ICH Q1A(R2) Guideline](https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf)
- [ICH Q1B Photostability Guideline](https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf)
- [ICH Q1D Bracketing/Matrixing Guideline](https://database.ich.org/sites/default/files/Q1D%20Guideline.pdf)
- [ICH Q1E Evaluation of Stability Data](https://database.ich.org/sites/default/files/Q1E_Guideline.pdf)
- [ICH Q5C Stability for Biologics](https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf)
- [ICH Q1 Draft Consolidated Guideline (Step 2, April 2025)](https://database.ich.org/sites/default/files/ICH_Q1EWG_Step2_Draft_Guideline_2025_0411.pdf)
- [ICH Q6B Specifications for Biologics](https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf)
- [ICH E2A Clinical Safety Data Management](https://database.ich.org/sites/default/files/E2A_Guideline.pdf)
- [ICH E2B(R3) ICSR Specification](https://ich.org/page/e2br3-individual-case-safety-report-icsr-specification-and-related-files)
- [ICH E2D(R1) Post-Approval Safety (Step 4, Aug 2025)](https://database.ich.org/sites/default/files/ICH_E2D%28R1%29_Step4_FinalGuideline_2025_0819.pdf)
- [ICH E2F DSUR Guideline](https://database.ich.org/sites/default/files/E2F_Guideline.pdf)
- [ICH E19 Selective Safety Data Collection](https://database.ich.org/sites/default/files/ICH_E19_Guideline_Step4_2022_0826_0.pdf)
- [ICH Quality Guidelines Overview](https://www.ich.org/page/quality-guidelines)

### MedDRA Sources
- [MedDRA Official Site](https://www.meddra.org/)
- [ICH MedDRA Page](https://ich.org/page/meddra)
- [MedDRA 28.1 Release Announcement](https://www.meddra.org/news-and-events/news/english-meddra-version-281-now-available-download)
- [MedDRA 28.0 Introductory Guide](https://alt.meddra.org/files_acrobat/intguide_28_0_English.pdf)

### CIOMS Sources
- [CIOMS I Form](https://cioms.ch/cioms-i-form/)
- [CIOMS Reporting Adverse Drug Reactions](https://cioms.ch/wp-content/uploads/2017/01/reporting_adverse_drug.pdf)
